MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Finance & Investment / Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.
Old Articles: <Older 49031-49040 Newer>
The Motley Fool
June 1, 2011
Dan Radovsky
I Bought Apple At $35: A Tale of Woe How one investor missed the Second Coming of Steve Jobs. mark for My Articles 151 similar articles
The Motley Fool
June 1, 2011
Seth Jayson
Here's Why 3M's Earnings Are Worse Than They Look With both 12-month and quarterly CCC running worse than average, 3M gets low marks in this cash-conversion checkup. mark for My Articles 759 similar articles
The Motley Fool
June 1, 2011
Here's What David Nierenberg's D3 Family of Funds Bought and Sold Last Quarter Learn from this hedge fund's top holdings and new trades. mark for My Articles 47 similar articles
The Motley Fool
June 1, 2011
Brian Stoffel
Secrets to Investing in These 7 Companies Use little-known sources of information to gain an edge. mark for My Articles 50 similar articles
The Motley Fool
June 1, 2011
Rick Aristotle Munarriz
5 Dates to Circle in June It's going to be a telltale month if you know what to look for in stock prices. mark for My Articles 356 similar articles
The Motley Fool
June 1, 2011
Seth Jayson
One Reason the Street Should Love Plains All American Pipeline's Earnings With both 12-month and quarterly CCC running better than average, Plains All American Pipeline gets high marks in this cash-conversion checkup. mark for My Articles 691 similar articles
The Motley Fool
June 1, 2011
Seth Jayson
How Fast Is the Cash at Enbridge Energy Partners? With quarterly CCC doing better than average and the latest 12-month CCC coming in worse, Enbridge Energy Partners gets a mixed review in this cash-conversion checkup. mark for My Articles 409 similar articles
The Motley Fool
June 1, 2011
Seth Jayson
One Reason the Street Should Love Abbott Laboratories' Earnings With both 12-month and quarterly CCC running better than average, Abbott Laboratories gets high marks in this cash-conversion checkup. mark for My Articles 709 similar articles
IEEE Spectrum
June 2011
Bob Garfield
The Revolution Will Not Be Monetized Stratospheric valuations for social media titans assume vast advertising revenue that will never arrive mark for My Articles 644 similar articles
The Motley Fool
May 31, 2011
Brian Orelli
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. mark for My Articles 1119 similar articles
<Older 49031-49040 Newer>    Return to current articles.